Ironwood Pharmaceuticals Expects FY24 Sales Between $435M-$455M Vs. 462.82M Estimate; Sees FY24 Adjusted EBITDA Above $150M
Portfolio Pulse from Benzinga Newsdesk
Ironwood Pharmaceuticals projects its FY24 sales to range from $435M to $455M, which is below the estimated $462.82M. Additionally, the company anticipates its FY24 adjusted EBITDA to exceed $150M.
February 15, 2024 | 12:13 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Ironwood Pharmaceuticals expects FY24 sales to be lower than analyst estimates but projects adjusted EBITDA to be above $150M.
The projected sales being lower than the analyst estimates could lead to a negative short-term reaction in the stock price due to investor concerns over growth. However, the positive outlook on adjusted EBITDA suggests operational efficiency and profitability, which might mitigate some negative impact.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100